Only cathelicidin antimicrobial peptide in humans. Studied for broad-spectrum antimicrobial, immunomodulatory, wound healing, and potential anticancer properties.
LL-37 is a human cathelicidin antimicrobial peptide — the only cathelicidin made by the human body. It is produced by immune cells and epithelial cells as part of the innate immune response. It has both direct antimicrobial activity and immune-modulating properties. Research has studied it in infection, wound healing, inflammatory conditions, and cancer biology.
Antimicrobial Research
LL-37 was originally identified for its ability to kill bacteria, fungi, viruses, and parasites by disrupting their cell membranes. Research has characterized its activity against drug-resistant bacteria, which has generated interest in it as a potential template for new antimicrobial compounds.
Wound Healing Research
LL-37 is produced at wound sites and plays a role in the healing response. Research has examined how LL-37 promotes cell migration, angiogenesis, and re-epithelialization at wounds. Some clinical interest has developed in topical LL-37 formulations for chronic wound management.
Immune Modulation Research
Beyond direct antimicrobial activity, LL-37 modulates the immune response in complex ways. It can be pro-inflammatory in some contexts (recruiting immune cells) and anti-inflammatory in others (modulating cytokine production). This dual role has implications for its research in inflammatory diseases.
Cancer Research
Research has examined LL-37's roles in cancer — sometimes appearing to inhibit tumor growth through immune stimulation, other times appearing to promote tumor progression in certain cancer types. Its biology in cancer contexts is complex and not yet fully resolved.
Broad antimicrobial activity against bacteria, fungi, and some viruses in laboratory studies.
Promotes wound healing through multiple mechanisms including angiogenesis and cell migration.
Complex immune-modulating effects that are context-dependent.
Mixed findings in cancer research — inhibitory in some contexts, potentially promotional in others.
Limited formal human clinical trial data for therapeutic applications.
LL-37 has a complex biology that makes it difficult to use as a straightforward therapeutic agent. Its immune effects are bidirectional depending on context. The cancer biology findings are concerning enough that unsupervised systemic use raises questions. Human therapeutic trials are limited. It is not FDA-approved for any application.
LL-37 is produced by your skin, lungs, and immune cells as a first responder against infections. It works by inserting itself into the membranes of bacteria and disrupting them — essentially punching holes in the invader's outer layer. It also sends signals to immune cells, telling them to come to the site of infection or injury. At wound sites, these signals also kick off healing processes by telling cells to grow and new blood vessels to form. LL-37's activity is not as simple as just killing pathogens — it is more like a multipurpose molecular alarm system that can turn up or dial down different aspects of the immune response depending on what is happening around it. This complexity makes it both interesting for research and challenging to develop as a drug.
LL-37 has not been evaluated in large human clinical trials. The cancer research findings — suggesting it may promote certain cancer types in some contexts — are a meaningful theoretical concern for systemic use. At inflammatory sites it can increase pro-inflammatory signaling. It is not FDA-approved for any use. The complexity of its biology makes its safety profile in diverse populations difficult to predict without more clinical research.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
The Cathelicidin Antimicrobial Peptide LL-37 Modulates Epithelial and Leukocyte Functions
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.